Veterans

Homecare Homebase Drives Agency Culture and Staff Empowerment for Optimal Home Care & HospiceHomecare Homebase Drives Agency Culture and Staff Empowerment for Optimal Home Care & Hospice

Homecare Homebase Drives Agency Culture and Staff Empowerment for Optimal Home Care & Hospice

DALLAS, March 11, 2025 /PRNewswire/ -- Homecare Homebase℠(HCHB), the leading software provider for home-based care, is highlighting how Optimal Home…

2 months ago
Advantum Health Recognized as one of Kentucky’s Best Places to Work for Second Consecutive YearAdvantum Health Recognized as one of Kentucky’s Best Places to Work for Second Consecutive Year

Advantum Health Recognized as one of Kentucky’s Best Places to Work for Second Consecutive Year

Advantum is named to the 21st Annual Best Places to Work in Kentucky list for 2025. LOUISVILLE, K.Y., March 11,…

2 months ago
genXtraits and Norfolk Healthy Produce to collaborate on breeding of nutritionally enhanced tomatoesgenXtraits and Norfolk Healthy Produce to collaborate on breeding of nutritionally enhanced tomatoes

genXtraits and Norfolk Healthy Produce to collaborate on breeding of nutritionally enhanced tomatoes

ALAMEDA ISLAND, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- genXtraits Inc. (genXtraits) and Norfolk Healthy Produce Inc. (NHP) today announced…

2 months ago
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsOvid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as…

2 months ago
The Joint Corp. Names SVP DevelopmentThe Joint Corp. Names SVP Development

The Joint Corp. Names SVP Development

Highly accomplished franchise development leader with over 20 years of experience to lead growth SCOTTSDALE, Ariz., March 11, 2025 (GLOBE…

2 months ago
Strength Beyond Service: Mind-Body Training Empowers San Antonio Veterans and First RespondersStrength Beyond Service: Mind-Body Training Empowers San Antonio Veterans and First Responders

Strength Beyond Service: Mind-Body Training Empowers San Antonio Veterans and First Responders

O2X Human Performance and Building Homes for Heroes Partner on Integrated Health Workshop LA VERNIA, Texas, March 10, 2025 /PRNewswire/ --…

2 months ago
Houston Methodist and HDAI speak to the promise of AI for addressing the healthcare crisis at the first annual HumanX conference in Las VegasHouston Methodist and HDAI speak to the promise of AI for addressing the healthcare crisis at the first annual HumanX conference in Las Vegas

Houston Methodist and HDAI speak to the promise of AI for addressing the healthcare crisis at the first annual HumanX conference in Las Vegas

LAS VEGAS, March 9, 2025 /PRNewswire/ -- C-suite leaders from Houston Methodist and Health Data Analytics Institute (HDAI) will be speaking at…

2 months ago
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AADDupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also…

2 months ago
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AADPress Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease…

2 months ago
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in PsoriasisLate-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and…

2 months ago